MIRADA MEDICAL LTD

Their core work

Mirada Medical is an Oxford-based SME that develops medical imaging software, with a core focus on oncology applications including radiotherapy treatment planning and quantitative image analysis. Their participation in the PREDICT project confirms their expertise in radiomics — the extraction of quantitative features from medical scans to support clinical decisions about diagnosis and treatment selection. They operate at the intersection of medical imaging technology and clinical decision support, translating complex image data into actionable information for clinicians. As a commercial software company embedded in academic research consortia, they bring production-ready tooling to research projects rather than pure scientific output.

What they specialise in

How they've shifted over time

Both recorded H2020 projects began in 2017, making a true temporal evolution analysis impossible — there is no early versus late split in this dataset. What can be inferred is that in 2017 Mirada Medical was simultaneously engaged in hard technical research (PREDICT, radiomics) and in soft-skills training for the next generation of researchers (HYBRID), suggesting a dual identity as both a technology provider and an industry mentor. Without projects from later years in this dataset, it is not possible to determine whether their H2020 engagement deepened, broadened, or ended after 2017.

Based on available data, Mirada Medical's trajectory points toward AI-assisted oncology imaging tools, but with only two projects from a single year, any trend claim would be speculative.

How they like to work

Mirada Medical has never coordinated an H2020 project — they join as a participant or silent third-party partner, which is typical for commercial SMEs that contribute a specific tool or platform rather than driving the scientific agenda. Despite this, they appear in consortia with up to 40 unique partners, indicating they are comfortable operating inside large, multi-institutional networks. This profile suggests they are reliable specialist contributors: they deliver a defined capability, leave coordination overhead to academic partners, and extract value through technology validation and visibility rather than administrative control.

Mirada Medical has collaborated with 40 unique partners across 10 countries through just two projects, which reflects the scale typical of MSCA Innovative Training Networks. Their reach is European in scope, though the Oxford base suggests natural density of UK and Western European connections.

What sets them apart

Mirada Medical occupies a rare position as a commercial medical imaging software company that participates directly in EU-funded research — most peers in this space stay outside academia entirely. This means they can offer a consortium both validated, deployable software and credibility with clinical end-users that a university spin-out cannot match. For a consortium building around imaging data or oncology workflows, they bring the product layer that transforms research outputs into something clinicians can actually use.

Highlights from their portfolio

• PREDICT
  The largest funded project (EUR 273,288) and the clearest expression of Mirada Medical's core business: radiomics-based clinical decision support in personalised cancer medicine.
• HYBRID
  An MSCA training network participation with no EC funding recorded, suggesting Mirada Medical contributed as an industry mentor — notable because it shows engagement beyond pure technology provision.